CTX001
VX21-CTX001-151
Phase 3 mab active
Quick answer
CTX001 for Sickle Cell Disease is a Phase 3 program (mab) at CRISPR Therapeutics AG with 2 ClinicalTrials.gov record(s).
Program details
- Company
- CRISPR Therapeutics AG
- Indication
- Sickle Cell Disease
- Phase
- Phase 3
- Modality
- mab
- Status
- active